Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) saw a large decrease in short interest in April. As of April 30th, there was short interest totalling 1,600,000 shares, a decrease of 37.0% from the April 15th total of 2,540,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is currently 0.7 days.
Shares of CALA opened at $0.23 on Friday. Calithera Biosciences has a twelve month low of $0.15 and a twelve month high of $2.59. The firm’s fifty day simple moving average is $0.37 and its 200-day simple moving average is $0.63.
Calithera Biosciences (NASDAQ:CALA – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). During the same quarter last year, the business earned ($0.28) earnings per share. Equities analysts expect that Calithera Biosciences will post -0.59 EPS for the current year.
A number of research firms have issued reports on CALA. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. StockNews.com began coverage on shares of Calithera Biosciences in a report on Thursday. They set a “hold” rating on the stock. LADENBURG THALM/SH SH reduced their target price on shares of Calithera Biosciences from $3.00 to $1.50 in a report on Wednesday. Finally, SVB Leerink reduced their target price on shares of Calithera Biosciences from $3.00 to $2.00 and set an “outperform” rating on the stock in a report on Monday, April 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.00.
Calithera Biosciences Company Profile (Get Rating)
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.